{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Protein Tyrosine Kinase/PTK > CrizotinibCAS：877399-52-5
Molecular Formula：C21H22Cl2FN5O
Molecular Weight：450.34
Storage：Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 877399-52-5 |
| Name | Crizotinib |
| Molecular Formula | C21H22Cl2FN5O |
| Molecular Weight | 450.34 |
| Solubility | Soluble in DMSO |
| Purity | HPLC≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 638-814-9 |
| MDL | MFCD12407409 |
| SMILES | ClC1=C(F)C=CC(Cl)=C1[C@H](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C |
| Target Point | ALK;c-Met/HGFR;ROS1 |
| Passage | Protein Tyrosine Kinase/RTK;Angiogenesis |
| Background | Crizotinib is a potent c-Met and ALK inhibitor as well as a ROS1 inhibitor. Crizotinib has potent tumor growth inhibitory effect and can be used in related research. |
| Biological Activity | Crizotinib是有效的 c-Met 和 ALK 抑制剂，在细胞试验中的 IC50 值分别为11 nM 和 24 nM。[1-8] |
| IC50 | 11nM(c-Met)，24nM(ALK)[1-8] |
| Data Literature Source | [1]. Zou HY，et al. An orally available small-molecule inhibitor of c-Met，PF-2341066，exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007，67(9)，4408-4417. [2]. Christensen JG，et al. Cytoreductive antitumor activity of PF-2341066，a novel inhibitor of anaplastic lymphoma kinase and c-Met，in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007，6(12 Pt 1)，3314-3322. [3]. Sampson ER，et al. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res. 2011，26(6)，1283-1294. [4]. Cullinane C，et al. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med. 2011 Aug;52(8):1261-7 [5]. Shen A，et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1;75(21):4548-59. [6]. Umapathy G，et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28;7(349):ra102. [7]. Tucker ER，et al. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol Oncol. 2017 Aug;11(8):996-1006. [8]. Liu H，et al. Identifying and Targeting Sporadic Oncogenic GeneticLiu H，et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369. |
| Unit | Bottle |
| Specification | 5mg 10mg 20mg 50mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
